Supplementary Material to:

The cyclin dependent kinase inhibitor Roscovitine prevents diet-induced metabolic disruption in obese mice

Nabil Rabhi¹, Kathleen Desevin¹, Briana Noel Cortez¹, Ryan Hekman², Jean Z. Lin¹, Andrew Emili² and Stephen R. Farmer^{1*}



Figure S1: (A) Fat mass determined by nuclear magnetic resonance (NMR) in 19-20 weeks LFD and HFD fed mice treated for 6 weeks with roscovitine or vehicle (n = 5 / group).



Figure S2: (**A**, **B**) Ambulatory activity measured by CLAMS in 19-20 weeks LFD (**A**) and HFD (**B**) fed mice treated for 6 weeks with roscovitine or vehicle (n = 5 / group). (**C**, **D**) Respiratory exchange ratio (RER) measured by CLAMS in 19-20 weeks LFD (**C**) and HFD (**D**) fed mice treated for 6 weeks with roscovitine or vehicle (n = 5 / group).



ĺ

D





Enrichment Results: Proteomics_RSW-VehW

0.25 0.50 0.75 Hits:Total (Pathway Features)

Enrichment Terms





Figure S3: (A) Heatmap of differential proteome in eWAT of 19-20 weeks LFD and HFD fed mice treated for 6 weeks with roscovitine or vehicle (n = 5 / group). (B) Volcano plot of up- and down-regulated proteins in eWAT from HFD mice treated with roscovitine compared to vehicle treated. (C) Volcano plot of up- and down-regulated phosphoproteins in eWAT from HFD mice treated with roscovitine compared to vehicle treated. (D) Dot plot of top enriched Go terms induced in eWAT from HFD mice treated with roscovitine compared to vehicle treated (E) Summary of kinase substrates proteins. Bar plots of mean of the phosphosites in each module are summarized for each condition. (F) Results of gene set enrichment analysis (GSEA) of up

regulated proteins and phosphoproteins in response to roscovitine treatment in eWAT from HFD mice visualized with Cytoscape Enrichment Map. Each node corresponds to a gene set either up-regulated (red) or down-regulated (blue). Edges (bleu lines) link sets with shared genes, and thickness of lines correlates with the number of genes in common between two sets. Only gene sets with FDR < 0.05 and p < 0.01 were included in visualizations.



BETA3 INTEGRIN CELL SURFACE INTERACTIONS MESENCHYMEDEVELOPMENT

IMMUNE EFFECTOR PROCESS REGULATION OF ATPASE GLYCOSAMINOGLYCAN METABOLISM MESENCHYMAL CELL DIFFERENTIATION PID_RB_1PATHWAY REGULATION OF PROTEIN

> POSITIVE REGULATION OF ATPASE ACTIVITY REGULATION OF PEPTIDE REGULATION OF SECRETION BY REGULATION OF RETINOBLASTOMA PROTEIN REGULATION OF HORMONE REGULATION OF SECRETION

Figure S4: (A) Heatmap of differential proteome in BAT of 19-20 weeks LFD and HFD fed mice treated for 6 weeks with roscovitine or vehicle (n = 5 / group). **(B)** Volcano plot of up- and down-regulated proteins in BAT from HFD mice treated with roscovitine compared to vehicle treated. **(C)** Volcano plot of up- and down-regulated phosphoproteins in BAT from HFD mice treated with roscovitine compared to vehicle treated. **(D)** Summary of kinase substrates proteins. Bar plots of mean of the phosphosites in each module are summarized for each condition. **(E)** Results of gene set enrichment analysis (GSEA) of up regulated proteins and phosphoproteins in response to roscovitine treatment in BAT from HFD mice visualized with Cytoscape Enrichment Map. Each node corresponds to a gene set either up-regulated (red) or down-regulated (blue). Edges (bleu lines) link sets with shared genes, and thickness of lines correlates with the number of genes in common between two sets. Only gene sets with FDR < 0.05 and p < 0.01 were included in visualizations.

 Table S3:
 SYBR green primers list

Fas F	AGCTGCAACTGTGCAAGGGTCTG
Fas R	TTGCCCAAGCATTGCCGCCTT
Scd 1 F	TTCTTGCGATACACTCTGGTGC
Scd 1 R	CGGGATTGAATGTTCTTGTCGT
Acc 1 F	ATGGGCGGAATGGTCTCTTTC
Acc 1 R	TGGGGACCTTGTCTTCATCAT
Acc2 F	CCTTTGGCAACAAGCAAGGTA
Acc 2	AGTCGTACACATAGGTGGTCC
Col1a1 F	TAAGGGTCCCCAATGGTGAGA
Col1a1 R	GGGTCCCTCGACTCCTACAT
Col3a1 F	CTGTAACATGGAAACTGGGGAAA
Col3a1 R	CCATAGCTGAACTGAAAACCACC
Col6a1 F	GACACCTCTCAGTGTGCTCTGT
Col6a1 R	GCGATAAGCCTTGGCAGGAAATG
Pgc1a F	GAAAACAGGAACAGCAGCAGAG
Pgc1a R	GGGGTCAGAGGAAGAGATAAAG
Dio 2 F	CAGTGTGGTGCACGTCTCCAA TC
Dio2 R	TGAACCAAAGTTGACCACCAG
UCP1 F	TCCTAGGGACCATCACCACCC
UCP1 R	AGCCGGCTGAGATCTTGTTTCC
Cox8b F	GAA CCA TGA AGC CAA CGA CT
Cox8b R	GCG AAG TTC ACA GTG GTT CC
Sma F	GTCCCAGACATCAGGGAGTAA
Sma R	TCGGATACTTCAGCGTCAGGA
Fn F	ATGTGGACCCCTCCTGATAGT
Fn R	GCCCAGTGATTTCAGCAAAGG
Cd 9 F	CTGGCATTGCAGTGCTTGCTA
Cd 9 R	AACCCGAAGAACAATCCCAGC
Mcp1 F	TTAAAAACCTGGATCGGAACCAA
Mcp1 R	GCATTAGCTTCAGATTTACGGGT
Tnfa F	GGTGCCTATGTCTCAGCCTCTT
Tnfa R	GCCATAGAACTGATGAGAGGGAG
F4/80 F	CGTGTTGTTGGTGGCACTGTGA